中国大陆发表meta分析2964篇分布如下：
数据来源 http://www.pubmedplus.cn/
01.randomized controlled trials as topic 2246 篇75.776% 02.treatment outcome 944 篇31.849% 03.risk factors 313 篇10.560% 04.meta-analysis as topic 268 篇9.042% 05.odds ratio 211 篇7.119% 06.postoperative complications 201 篇6.781% 07.clinical trials as topic 194 篇6.545% 09.time factors 149 篇5.027% 10.length of stay 126 篇4.251% 11.drug therapy, combination 125 篇4.217% 12.antineoplastic combined chemotherapy protocols 123 篇4.150% 13.drugs, chinese herbal 123 篇4.150% 14.publication bias 120 篇4.049% 15.survival rate 119 篇4.015% 16.case-control studies 116 篇3.914% 17.lung neoplasms 111 篇3.745% 18.genetic predisposition to disease 110 篇3.711% 20.antineoplastic agents 108 篇3.644% 21.risk assessment 99 篇3.340% 22.disease-free survival 93 篇3.138% 24.myocardial infarction 86 篇2.901% 26.survival analysis 85 篇2.868% 27.carcinoma, non-small-cell lung 84 篇2.834% 29.dietary supplements 81 篇2.733% 30.evidence-based medicine 81 篇2.733% 31.stomach neoplasms 81 篇2.733% 32.antibodies, monoclonal, humanized 80 篇2.699% 33.databases, factual 80 篇2.699% 34.laparoscopy 80 篇2.699% 35.cardiovascular diseases 78 篇2.632% 37.colorectal neoplasms 76 篇2.564% 38.combined modality therapy 75 篇2.530% 39.prospective studies 75 篇2.530% 40.polymorphism, single nucleotide 72 篇2.429% 41.polymorphism, genetic 71 篇2.395% 42.diabetes mellitus, type 2 70 篇2.362% 43.phytotherapy 69 篇2.328% 44.quality of life 69 篇2.328% 45.follow-up studies 68 篇2.294% 46.anti-bacterial agents 65 篇2.193% 48.dose-response relationship, drug 61 篇2.058% 49.breast neoplasms 60 篇2.024% 50.pain, postoperative 58 篇1.957% 01.drugs, chinese herbal 123 篇4.150% 02.antineoplastic agents 108 篇3.644% 03.antibodies, monoclonal, humanized 80 篇2.699% 04.anti-bacterial agents 65 篇2.193% 05.hydroxymethylglutaryl-coa reductase inhibitors 55 篇1.856% 06.antibodies, monoclonal 50 篇1.687% 07.antiviral agents 46 篇1.552% 08.antihypertensive agents 44 篇1.484% 09.immunosuppressive agents 44 篇1.484% 10.hypoglycemic agents 41 篇1.383% 11.deoxycytidine 37 篇1.248% 12.blood glucose 35 篇1.181% 13.bevacizumab 34 篇1.147% 14.angiogenesis inhibitors 31 篇1.046% 15.biological markers 30 篇1.012% 16.protein kinase inhibitors 30 篇1.012% 18.fluorouracil 29 篇0.978% 19.platelet aggregation inhibitors 29 篇0.978% 20.receptor, epidermal growth factor 29 篇0.978% 21.gemcitabine 28 篇0.945% 25.anti-inflammatory agents, non-steroidal 25 篇0.843% 26.bone density conservation agents 25 篇0.843% 27.hemoglobin a, glycosylated 25 篇0.843% 28.triglycerides 25 篇0.843% 29.anticoagulants 24 篇0.810% 30.cholesterol 24 篇0.810% 31.vascular endothelial growth factor a 24 篇0.810% 33.adrenal cortex hormones 22 篇0.742% 34.c-reactive protein 22 篇0.742% 35.drug combinations 22 篇0.742% 36.fibrinolytic agents 22 篇0.742% 37.sulfonamides 22 篇0.742% 38.cholesterol, ldl 21 篇0.709% 40.recombinant proteins 21 篇0.709% 42.angiotensin-converting enzyme inhibitors 20 篇0.675% 43.interferon-alpha 20 篇0.675% 44.quinazolines 20 篇0.675% 46.tumor necrosis factor-alpha 20 篇0.675% 47.fatty acids, omega-3 19 篇0.641% 48.glucocorticoids 19 篇0.641% 49.organoplatinum compounds 19 篇0.641% 50.tumor markers, biological 19 篇0.641% 12.女性泌尿生殖器疾病和妊娠并发症 236 篇7.962%
https://blog.sciencenet.cn/blog-280034-995130.html
上一篇：
韩春雨 如果你造假，我照样坚决批判！下一篇：
2016世界生命科学大会
